ClinicalTrials.gg
RecruitingNCT07186452Updated Jan 16, 2026

Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HS-20093 and Itraconazole in Advanced Solid Tumors, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the effect of itraconazole on the pharmacokinetics of HS-20093 in patients with advanced solid tumors.

Read the detailed description

This is a multicenter, open-label, non-randomized, fixed-sequence, self-controlled clinical study designed to evaluate the effect of itraconazole on the pharmacokinetics of HS-20093 in patients with advanced solid tumors who have failed or are intolerant to standard therapy.

All participants will receive intravenous infusion of HS-20093 at a dose of 8 mg/kg every 3 weeks (Q3W), with each treatment cycle lasting 21 days. Participants will then take itraconazole capsules orally at 200 mg per dose during C2D17-C3D21

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed advanced solid tumors that have failed standard therapy or are intolerant to standard treatment.
  2. According to 1.1 criteria, participants must have at least one target lesion.
  3. performance status score of 0-1 with no deterioration within 2 weeks prior to the first dose.
  4. Minimum expected survival greater than 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a for receiving itraconazole according to the prescribing information
  2. Patients with severe, uncontrolled, or active cardiovascular diseases
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    HS-20093 + Itraconazole

    Drug: HS-20093 · Drug: Itraconazole

Interventions

  • All participants will receive intravenous infusion of HS-20093 at a dose of 8 mg/kg every 3 weeks (Q3W), with each treatment cycle lasting 21 days.

  • Participants will then take itraconazole capsules orally at 200 mg per dose during C2D17-C3D21

06

What researchers measure

Primary outcomes

  1. Cmax of HS-20093 and free toxin

    Maximum concentration of HS-20093 and free toxin, measured by appropriate analytical methods.

    Time frame: Three treatment cycles, each cycle lasting for three weeks.

  2. AUC0-16d of HS-20093 and free toxin

    Area under the concentration-time curve from time zero to 16 days of HS-20093 and free free toxin, calculated by non-compartmental analysis.

    Time frame: Three treatment cycles, each cycle lasting for three weeks.

Secondary outcomes

  1. Tmax of HS-20093 and free toxin

    Time to reach maximum concentration of HS-20093 and free toxin, derived directly from observed concentration-time data.

    Time frame: Three treatment cycles, each cycle lasting for three weeks.

  2. t1/2 of HS-20093 and free toxin

    Terminal elimination half-life of HS-20093 and free toxin.

    Time frame: Three treatment cycles, each cycle lasting for three weeks.

  3. AUC0-∞ and AUC0-tau of HS-20093 and free toxin

    Area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) and during the dosing interval (AUC0-tau) of HS-20093 and free toxin.

    Time frame: Three treatment cycles, each cycle lasting for three weeks.

  4. Cmin of HS-20093 and free toxin

    Minimum observed concentration of HS-20093 and free toxin.

    Time frame: Three treatment cycles, each cycle lasting for three weeks.

  5. CL of HS-20093 and free toxin

    Clearance of HS-20093 and free toxin.

    Time frame: Three treatment cycles, each cycle lasting for three weeks.

  6. V of HS-20093 and free toxin

    Volume of distribution of HS-20093 and free toxin.

    Time frame: Three treatment cycles, each cycle lasting for three weeks.

  7. Incidence and severity of adverse events (AEs)

    AE assessed by investigator exclusively related to subject's underlying disease or medical condition \[graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0\]. Any untoward medical occurrence in a clinical study participant, whether or not considered related to the medicinal product. Incidence and severity of AEs are assessed according to vital signs, laboratory variables, physical examination, electrocardiogram, etc.

    Time frame: Screening to 90 days post-last dose

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 22, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Aug 31, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07186452
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Sep 23, 2025
Primary completion
Jul 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Jan 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risvutatug rezetecan

Start the discussion